Feb 5, 2026
where do ribociclib, palbociclib and abemaciclib sit in treatment guidelines?
Three —, and —sit firmly as the standard first-line systemic option for HR‑positive, HER2‑negative advanced/metastatic breast cancer when combined with endocrine therapy, with guideline bodies and ran...